Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

•Quality of life was assessed in 26 XLH patients before and after 4 months of treatment with KRN23.•All mean scores showed a trend of improved health after 4 doses of KRN23 treatment.•Role limitations due to physical health was significantly improved after multiplicity correction.•Patient reported o...

Full description

Bibliographic Details
Main Authors: Ruppe, Mary D., Zhang, Xiaoping, Imel, Erik A., Weber, Thomas J., Klausner, Mark A., Ito, Takahiro, Vergeire, Maria, Humphrey, Jeffrey S., Glorieux, Francis H., Portale, Anthony A., Insogna, Karl, Peacock, Munro, Carpenter, Thomas O.
Format: Online
Language:English
Published: Elsevier 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926842/
id pubmed-4926842
recordtype oai_dc
spelling pubmed-49268422017-03-21 Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia Ruppe, Mary D. Zhang, Xiaoping Imel, Erik A. Weber, Thomas J. Klausner, Mark A. Ito, Takahiro Vergeire, Maria Humphrey, Jeffrey S. Glorieux, Francis H. Portale, Anthony A. Insogna, Karl Peacock, Munro Carpenter, Thomas O. Article •Quality of life was assessed in 26 XLH patients before and after 4 months of treatment with KRN23.•All mean scores showed a trend of improved health after 4 doses of KRN23 treatment.•Role limitations due to physical health was significantly improved after multiplicity correction.•Patient reported outcomes can provide valuable information in evaluating new treatments for XLH. Elsevier 2016-05-13 /pmc/articles/PMC4926842/ /pubmed/28326356 http://dx.doi.org/10.1016/j.bonr.2016.05.004 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Ruppe, Mary D.
Zhang, Xiaoping
Imel, Erik A.
Weber, Thomas J.
Klausner, Mark A.
Ito, Takahiro
Vergeire, Maria
Humphrey, Jeffrey S.
Glorieux, Francis H.
Portale, Anthony A.
Insogna, Karl
Peacock, Munro
Carpenter, Thomas O.
spellingShingle Ruppe, Mary D.
Zhang, Xiaoping
Imel, Erik A.
Weber, Thomas J.
Klausner, Mark A.
Ito, Takahiro
Vergeire, Maria
Humphrey, Jeffrey S.
Glorieux, Francis H.
Portale, Anthony A.
Insogna, Karl
Peacock, Munro
Carpenter, Thomas O.
Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
author_facet Ruppe, Mary D.
Zhang, Xiaoping
Imel, Erik A.
Weber, Thomas J.
Klausner, Mark A.
Ito, Takahiro
Vergeire, Maria
Humphrey, Jeffrey S.
Glorieux, Francis H.
Portale, Anthony A.
Insogna, Karl
Peacock, Munro
Carpenter, Thomas O.
author_sort Ruppe, Mary D.
title Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
title_short Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
title_full Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
title_fullStr Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
title_full_unstemmed Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia
title_sort effect of four monthly doses of a human monoclonal anti-fgf23 antibody (krn23) on quality of life in x-linked hypophosphatemia
description •Quality of life was assessed in 26 XLH patients before and after 4 months of treatment with KRN23.•All mean scores showed a trend of improved health after 4 doses of KRN23 treatment.•Role limitations due to physical health was significantly improved after multiplicity correction.•Patient reported outcomes can provide valuable information in evaluating new treatments for XLH.
publisher Elsevier
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926842/
_version_ 1613601702041092096

Similar Items